Advanced Clinical Announces New Executive Vice President
News Apr 22, 2013
Advanced Clinical has announced an addition to its leadership team: Julie A. Ross, has been hired as Executive Vice President, CRO Operations.
Julie Ross is a tenured executive leader who has been instrumental in the development and the success of multiple clinical operations divisions.
Previously with inVentiv Health Clinical (formerly Pharmanet/i3), Ms. Ross served as Senior Vice President, Global Strategic Services and had oversight of Feasibility, Patient Recruitment and Retention, Global Study Start-up, Document Management and Publishing, Expedited Safety Reporting, Grants and Contracts, Clinical Trial Supply Management and Medical Writing.
Prior to her role at inVentiv, Ms. Ross led Essential Group, a full-service CRO and patient recruitment company, which she helped build and position for its acquisition by inVentiv Health.
“We are very excited to welcome Julie to the Advanced Clinical team,” said Leo Sheridan, CEO of Advanced Clinical. “We are honored to bring Julie’s caliber and experience to our team as we continue expanding our CRO solutions. Her diverse knowledge and expertise in clinical research, as well as her strong leadership skills, are a perfect fit for Advanced Clinical.”
A graduate of the University of Wisconsin, La Crosse with a bachelor's degree in Nuclear Medicine Technology, Ms. Ross has been in the clinical research industry for over twenty five years.
She has authored many clinical research articles and is a well-known industry speaker. Ms. Ross will be based out of Advanced Clinical’s headquarters in Deerfield, IL.
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Cocaine Use Alters Gene Expression in Brain Reward CircuitsNews
A study in Biological Psychiatry investigates transcriptome-wide alterations in response to cocaine self-administration in mice.
Ipsen and MD Anderson Announce Bench-to-Bedside Cancer Drug Development PartnershipNews
MD Anderson will progress the drug candidate through Phase I clinical development with Ipsen being responsible for further global development and commercialization.READ MORE
Comments | 0 ADD COMMENT
10th Annual Congress on Drug Formulation & Analytical Techniques
Sep 03 - Sep 04, 2018